Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
- Sorrento Therapeutics Inc (NASDAQ:SRNE) entered into a research collaboration agreement with Mayo Clinic to conduct human clinical proof of concept studies using the Sofusa Lymphatic Drug Delivery System (S-LDDS) technology.
- Sofusa is a drug delivery platform that delivers biologic therapies through the skin and directly into the lymphatic system, potentially improving the efficacy and safety of immuno-oncology therapies.
- Targeting delivery to the lymphatics should also enable reduced dosing compared to traditional systemic infusions or subcutaneous injections.
- The first study resulting in this agreement is MC20711, a Phase 1b study of the administration of Ipilimumab Intra-Lymphatically using the Sofusa DoseConnect in Patients with Metastatic Melanoma.
- This agreement builds upon the previously announced exclusive licensing agreement where Sorrento licensed Mayo Clinic's Antibody-Drug-Nanoparticle albumin-bound Immune Complex platform technology.
- Price Action: SRNE shares are up 5.75% at $9.38 in the premarket session on the last check Monday.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!